Teleflex (NYSE:TFX) Lowered to “Strong Sell” Rating by Zacks Research

Teleflex (NYSE:TFX) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Monday,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research report on Monday, December 29th. Needham & Company LLC boosted their target price on shares of Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Royal Bank Of Canada raised their price target on Teleflex from $115.00 to $125.00 and gave the stock a “sector perform” rating in a research note on Friday, February 27th. Truist Financial lifted their price objective on Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a report on Thursday, December 18th. Finally, Wells Fargo & Company increased their target price on Teleflex from $116.00 to $130.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Teleflex presently has an average rating of “Hold” and a consensus target price of $140.83.

Teleflex Trading Down 0.7%

Shares of NYSE:TFX opened at $122.02 on Monday. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.54 and a quick ratio of 2.01. Teleflex has a 1 year low of $100.18 and a 1 year high of $143.32. The company has a market cap of $5.39 billion, a P/E ratio of -5.94, a PEG ratio of 0.76 and a beta of 0.87. The stock’s fifty day moving average price is $111.31 and its 200-day moving average price is $118.70.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 EPS for the quarter, missing the consensus estimate of $3.73 by ($1.80). The business had revenue of $569.00 million during the quarter, compared to the consensus estimate of $912.57 million. Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.Teleflex’s quarterly revenue was down 28.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.89 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Sell-side analysts expect that Teleflex will post 13.98 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. MassMutual Private Wealth & Trust FSB grew its stake in shares of Teleflex by 57.9% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock valued at $26,000 after acquiring an additional 77 shares during the period. Banque Cantonale Vaudoise lifted its holdings in Teleflex by 82.5% during the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after purchasing an additional 113 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in Teleflex by 248.8% during the third quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after purchasing an additional 199 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Teleflex in the third quarter worth approximately $35,000. Finally, True Wealth Design LLC increased its stake in shares of Teleflex by 10,333.3% in the second quarter. True Wealth Design LLC now owns 313 shares of the medical technology company’s stock worth $37,000 after purchasing an additional 310 shares in the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.